NCT04827992 2025-11-05
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
Massachusetts General Hospital
Phase NA Completed
Clinical Trials
10 trialsNCT03948074 2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2 Completed
NCT05663346 2025-02-14
Cannabis and Cancer, an Online Training for Oncology Nurses
Ciusss de L'Est de l'Île de Montréal
Phase NA Completed
NCT00675948 2023-05-03
Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain
Jazz Pharmaceuticals
Phase 3 Completed
NCT01337089 2023-04-12
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Jazz Pharmaceuticals
Phase 3 Completed
NCT01361607 2023-04-12
SPRAY III
Jazz Pharmaceuticals
Phase 3 Completed
NCT01424566 2023-04-12
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 3 Completed
NCT01812603 2022-12-20
A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT01812616 2022-12-20
A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT01983267 2017-05-08
Evaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use.
Rambam Health Care Campus
Phase NA Completed